The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...

Sanofi and CD&R have signed a share purchase agreement for the sale of a 50% stake in the consumer health business.

Sanofi and CD&R sign Opella share purchase agreementParis, February 19, 2025. Following completion of the required social and corporate ...

Execution of a share buyback agreement for up to €2 billion Paris, February 7, 2025. On January 30, 2025 (https://www.sanofi.com/en/media-room/press-releases/2025/ ...

In 2024, Sanofi (NASDAQ:SNY) worked hard to become primarily a biopharma company, which included selling a dominant stake in Opella, a major company in the over-the-counter and vitamins ...

We recently compiled a list of the 10 Best Foreign Stocks With Dividends For Passive Income. In this article, we are going to take a look at where Sanofi (NASDAQ:SNY) stands against the other foreign ...

OpenAI’s big rebranding effort brings a new logo and a new typeface, OpenAI sans. OpenAI’s big rebranding effort brings a new logo and a new typeface, OpenAI sans. Emma Roth is a news writer ...

L’Oreal OR-1.27%decrease; red down pointing triangle will sell part of its stake in Sanofi SAN-0.21%decrease; red down pointing triangle back to the French pharmaceutical company for 3 billion ...

In October 2024, Sanofi entered talks with US private equity company Clayton Dubilier & Rice (CD&R) over the sale of Opella, valued at around $17bn. A deal is slated to be completed by Q2 this year.

AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company takes its lead candidate through a prostate cancer trial. The Pb-212 ...

A €5 billion share buyback program is planned for 2025, aiming to offset Opella dilution and enhance ... potentially impacting market share. Sanofi delivered robust Q4 2024 results with strong ...